Retraction Retraction dated 2023-12-11
Click to view Retraction: https://doi.org/10.1038/s41467-023-43803-0
Retraction Retraction dated 2023-12-11
Click to view Retraction: https://doi.org/10.1038/s41467-023-43803-0
-
Authors
Patterson-Fortin, Jeffrey
Jadhav, Heta
Pantelidou, Constantia
Phan, Tin
Grochala, Carter https://orcid.org/0000-0001-8064-1913
Mehta, Anita K.
Guerriero, Jennifer L. https://orcid.org/0000-0002-2104-5457
Wulf, Gerburg M. https://orcid.org/0000-0001-7868-6231
Wolpin, Brian M. https://orcid.org/0000-0002-0455-1032
Stanger, Ben Z. https://orcid.org/0000-0003-0410-4037
Aguirre, Andrew J. https://orcid.org/0000-0002-0701-6203
Cleary, James M.
D’Andrea, Alan D. https://orcid.org/0000-0001-6168-6294
Shapiro, Geoffrey I. https://orcid.org/0000-0002-3331-4095
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA272982)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA127003)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA186504)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA006516)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Lustgarten Foundation
Breast Cancer Research Foundation
Fanconi Anemia Research Fund
Ludwig Institute for Cancer Research
Richard and Susan Smith Family Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 27 September 2022
Accepted: 2 March 2023
First Online: 13 March 2023
Change Date: 11 December 2023
Change Type: Correction
Change Details: This article has been retracted. Please see the Retraction Notice for more detail:
Change Details: https://doi.org/10.1038/s41467-023-43803-0
Competing interests
: J.L.G. is a consultant for Glaxo-Smith Kline (GSK), Codagenix, Verseau Therapeutics, Kymera, Kowa, Duke Street Bio., and Array BioPharma and receives sponsored research support from GSK, Array BioPharma, Merck and Eli Lilly. G.M.W. reports research funding from Merck & Co, institutional funding from Glaxo Smith Kline and Genentech, and US patent 20090258352, “A1 Pin1 as a marker for abnormal l cell growth,” licensed to Cell Signaling and R&D Systems. B.M.W. receives Research support from Celgene, Eli Lilly, Novartis, and Revolution Medicine; Consulting for Celgene, GRAIL, and Mirati. A.J.A. has consulted for Oncorus, Inc., Arrakis Therapeutics, Syros Pharmaceuticals, Boehringer Ingelheim, T-knife Therapeutics, AstraZeneca, Mirati Therapeutics, Revolution Medicines, Anji Pharmaceuticals, and Merck & Co., Inc. A.J.A. consults for and holds equity in Riva Therapeutics. A.J.A. has research funding from Mirati Therapeutics, Syros Pharmaceuticals, Bristol Myers Squibb, Revolution Medicines, Novartis, Novo Ventures and Deerfield, Inc. J.M.C. receives research funding to his institution from Merus, Roche, and Bristol Myers Squibb. He receives research support from Merck, AstraZeneca, Esperas Pharma, Bayer, Tesaro, Arcus Biosciences, and Apexigen; he received honoraria for being on advisory boards of Syros Pharmaceuticals, Incyte, and Blueprint Medicines. A.D.D. reports consulting for AstraZeneca, Bayer AG, Blacksmith/Lightstone Ventures, Bristol Myers Squibb, Cyteir Therapeutics, EMD Serono, Impact Therapeutics, PrimeFour Therapeutics, Pfizer, Tango Therapeutics, and Zentalis Pharmaceuticals/Zeno Management; is an Advisory Board member for Cyteir, and Impact Therapeutics; stockholder in Cedilla Therapeutics, Cyteir, Impact Therapeutics, and PrimeFour Therapeutics; and reports receiving commercial research grants from Bristol Myers Squibb, EMD Serono, Moderna, and Tango Therapeutics. G.I.S. has received research funding from Eli Lilly, Merck KGaA/EMD-Serono, Merck & Co., and Pfizer. He has served on advisory boards for Pfizer, Eli Lilly, Merck KGaA/EMD-Serono, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Bayer, Boehringer Ingelheim, ImmunoMet, Artios, Atrin, Concarlo Holdings, Syros, Zentalis, CytomX Therapeutics, Blueprint Medicines, Kymera Therapeutics, Janssen and Xinthera. In addition, he holds a patent entitled, “Dosage regimen for sapacitabine and seliciclib,” also issued to Cyclacel Pharmaceuticals, and a pending patent, entitled, “Compositions and Methods for Predicting Response and Resistance to CDK4/6 Inhibition,” together with Liam Cornell. The remaining authors declare no competing interests.
